CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 87 enrolled
Drug / intervention
Intranasal Insulindrug
Likely dose
Intranasal Insulin 40 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03943537
NCT03943537Phase 2Completed
CompareCT.gov

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

Mclean Hospital·interventional·Posted May 9, 2019·Updated Apr 15, 2025

In Brief

A Phase 2 clinical trial evaluating Intranasal Insulin for Psychosis and 3 related conditions. Completed, enrolled 87 participants across 1 site.

Detailed Summary

This clinical trial is a single center, single dose study of the acute effects of intranasal insulin on energy metabolism and cognitive function in patients with schizophrenia, schizoaffective and bipolar disorders, compared and healthy controls.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsychosis, Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 9, 2019
Enrollment StartOct 1, 2019
Primary CompletionFeb 23, 2024
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 7.1 years ago

Interventions

Intranasal Insulindrug

40 units Novolin R administered intranasally using ViaNase device.